Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
about
Muscle-invasive urothelial bladder cancer: an update on systemic therapyOptimal management of muscle-invasive bladder cancer - a reviewMultimodal management of muscle-invasive bladder cancerSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors.The National Cancer Data Base: a powerful initiative to improve cancer care in the United StatesAssociation of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base.Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions.Defining the potential of neoadjuvant chemotherapy use as a quality indicator for bladder cancer care.Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guidelineOptimal timing of chemotherapy and cystectomy.ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapySomatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinomaMaximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy.Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States.Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapyProgress in personalizing chemotherapy for bladder cancerNeoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion.Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practiceA role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experienceCurrent status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy.The Role of Population-Based Observational Research in Bladder CancerConcordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study.The role of chemotherapy in upper tract urothelial carcinoma.Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.Optimizing care and outcomes of patients with muscle-invasive bladder cancer.Pharmacogenomics in bladder cancer.Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.Molecular signatures that predict nodal metastasis in bladder cancer: does the primary tumor tell tales?A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer.Urothelial carcinoma of the bladder: definition, treatment and future efforts.Urothelial cancers: using biology to improve outcomes.Neoadjuvant chemotherapy for invasive bladder cancer.Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review.
P2860
Q26775780-0DB3E90D-AC2A-42CD-8752-4B433498BE2AQ26784038-6EB05E57-D458-447E-9399-9A743CB72333Q27011624-27B0C822-B930-42CC-8DB1-7BCA86E225CFQ30240816-4AA77EAC-F982-4E00-B948-98BFBFCA68DBQ30421675-4597A562-CD11-4822-A0B0-3C33CB33993AQ30485127-CCA10EB4-41B1-4F24-B382-C0980E55AD97Q31142308-92BEFCBA-6D71-4592-99D5-514687DF4043Q33605299-381AC1E6-1793-4EFF-8E2A-A66E6FA6CB6AQ33662842-EF594197-0382-413E-80EF-B00473F4F982Q33758673-6672DE80-4225-41D0-9CE9-C9E2CF58E182Q34021124-D9227F05-E095-4A27-8C0D-688429D9AEA1Q34023055-E07937A2-9D00-4C24-A6D2-E47517F34DF2Q34175543-FFDD6200-9E47-480F-BDC8-89BF284D8F0FQ34278209-DB627145-0C32-4EBF-A2E8-265BF02DF8E3Q34549516-54B1294D-AB25-4414-B4C5-4C162C1A74B2Q35109085-6D6C7C0E-4BDA-4EAF-8859-AA350FCC77DCQ35748060-2FEB1F4E-761D-4A81-BD84-78692ED9FB6CQ35748071-B3CAC7A6-E144-472D-A86B-7AF5EF1BD49FQ35771672-71E73F4E-91D9-43D7-A72B-886065BBD0C8Q35779460-7811C245-089E-41CC-8F7F-DEAACA73AB37Q36628852-2893C812-52EA-49A7-BB29-2DA90B0AEACEQ36631963-A2A471C9-3B70-4977-9DB4-950759BA92B1Q36979001-7B21FF93-F2DA-4B7E-B48D-D00A7BDFB37EQ37025948-0B7B8416-404A-4E9D-B042-81855204F4BAQ37033304-9A1C8DB2-1655-4A57-B919-68644F9BA2A6Q37053750-F73844C0-EA4E-4174-ABE0-6FCEC70213B1Q37053926-D3599903-0351-431A-A22C-7010DC64CBE5Q37071515-FF338E65-8F42-4537-968D-905A134C1DCAQ37128756-4FABD71B-3698-4124-AE24-9CC21800BF94Q37411206-964FD61F-7890-41CA-A5D9-55ED0E046D0FQ37455252-D5690DE3-1AA5-4732-89AA-6CE69AF7EEEFQ37523551-479FD060-26D7-482F-A0BB-B00E6DB09BF8Q37601376-4A0BDAC3-0405-4BEC-A684-1CD15B16F3EEQ37735161-685949FB-A60B-4190-9D8F-C36820DE466EQ37894668-37839E45-C861-40CA-8ACA-764853A731FFQ37896014-D06F5468-5E24-4A5A-9A17-C332FD88FC98Q37944437-591F332A-3668-4509-A0E1-6C919B58D3BEQ37965638-8E1459A2-B4FC-47F4-A489-4E1F501BCE21Q37982318-2CF48B33-D115-47D8-A201-BEB8AE0D3722Q38051010-F6B5A4E6-33D4-472A-BFC0-56B92E8E481C
P2860
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Low incidence of perioperative ...... the National Cancer Data Base.
@ast
Low incidence of perioperative ...... the National Cancer Data Base.
@en
type
label
Low incidence of perioperative ...... the National Cancer Data Base.
@ast
Low incidence of perioperative ...... the National Cancer Data Base.
@en
prefLabel
Low incidence of perioperative ...... the National Cancer Data Base.
@ast
Low incidence of perioperative ...... the National Cancer Data Base.
@en
P2093
P1476
Low incidence of perioperative ...... the National Cancer Data Base.
@en
P2093
David M Nanus
Jamie Ritchey
Kevin A David
Matthew I Milowsky
Peter R Carroll
P304
P356
10.1016/J.JURO.2007.03.101
P407
P577
2007-06-11T00:00:00Z